Immunology of Cellular and Humoral Rejection after Cardiac Transplantation

  • Marlene L. Rose
  • Sudhir Kushwaha
  • Deirdre Cunningham


The major complication following cardiac transplantation remains acute and chronic allograft rejection. Rejection is mediated both by cells and antibody, the different components of the immune response predominating at different times. It is interesting to note that, in the early days of human cardiac transplantation, detection of antibodies was considered to be the most obvious way to monitor the recipient’s immune response. In a report published during that time,1 it was found using an indirect immunofluorescent staining technique in a study of 5 patients surviving for more than 7 days after cardiac transplantation that serum samples from these patients contained antibodies directed against components of cardiac myofibres. These antibodies were detected early (4 or 5 days) after transplantation and their presence appeared to correlate with clinical signs of rejection.


Acute Rejection Allograft Rejection Cardiac Transplantation Rejection Episode Endomyocardial Biopsy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ellis RJ, Lillehei CW, Fischetti VA, et al. Heart-reactive antibody: an index of cardiac rejection in human heart transplantation. Circulation 1970;42 (Supplement II) II-91–II-97.Google Scholar
  2. 2.
    Rose ML, Gracie JA, Fraser A, Chisholm P, Yacoub MH. Use of monoclonal antibodies to quantitate T lymphocyte subpopulations in human cardiac allografts. Transplantation 1984;38: 230–4.PubMedGoogle Scholar
  3. 3.
    Hoshinaga K, Mohanakumar T, Goldman MH, et al. Clinical significance of in situ detection of T lymphocyte subsets and monocyte/macrophage lineages in heart allografts. Transplantation 1984;38:634–7.PubMedGoogle Scholar
  4. 4.
    Rose ML, Page C, Hengstenberg C, Yacoub MH. Identification if antigen presenting cells in normal and transplanted human heart: Importance of endothelial cells. Human Immunology 1990;28: 179–85.PubMedGoogle Scholar
  5. 5.
    Imakita M, Cohnert TR, Billingham ME. Endocardial infiltrates: the “Quilty” effect. J Heart Transplant 1988;7:57–61.Google Scholar
  6. 6.
    Pardo-Mindan FJ, Lozano MD. “Quilty effect” in heart transplantation: Is it related to acute rejection? J Heart Transplant 1991;10:937–91.Google Scholar
  7. 7.
    Kemnitz J, Cohnert TR. Lymphoma-like lesion in human orthotopic cardiac allografts. Am J Clin Path 1988;89:430 (Abstract).Google Scholar
  8. 8.
    Nakhleh RE, Copenhaver CM, Werdin K, McDonald K, Kubo S, Strickler JG. Lack of evidence for involvement of Epstein-Barr virus in the development of the “Quilty” lesion of transplanted hearts: an in situ hybridization study. J Heart Transplant 1991:10:504–7.Google Scholar
  9. 9.
    DeLourdes P, Higuchi M, Campas de Assis RV, et al. Usefulness of T cell phenotype characteristics in endomyocardial biopsy fragments from human cardiac allografts. J Heart Lung Transplant 1991;10:235–42.Google Scholar
  10. 10.
    Podack ER, Young JD, Conn ZA. Isolation and biochemical and functional characterization of perforin 1 from cytolytic T cell granules. Proc Natl Acad Science 1985;82:8629–33.Google Scholar
  11. 11.
    Mueller C, Shelby J, Weissman IL, Peinat-Frey T, Eichwald EJ. Expression of the protease gene HF as a marker in rejecting allogeneic murine heart transplants. Transplantation 1991;51:514–7.PubMedGoogle Scholar
  12. 12.
    Griffiths GM, Namikawa R, Mueller C, Liu CC, Young JE, Billingham M, Weissman I. Granzyme A and perforin as markers of rejection in cardiac transplantation. Eur J Immunology 1991;21: 687–92.Google Scholar
  13. 13.
    Yoshinori S, Shinkai Y, Kawasaki A, Yagita H, Okumura K, Takaku F, Yazaki Y. Expression of perforin in infiltrating cells in murine hearts with acute myocarditis caused by Coxsackievirus B3. Circulation 1991;84:788–95.Google Scholar
  14. 14.
    Suitters AJ, Rose ML, Dominguez MJ, Yacoub MH. Selection of donor specific cytotoxic T cells within the allografted human heart. Transplantation 1990;49:1105–9.PubMedGoogle Scholar
  15. 15.
    Salmon RN, Maguire JA, Esmore D, Hancock WH. Analysis of proliferating cell nuclear antigen expression aids histologic diagnosis and is predictive of progression of human cardiac allograft rejection. Am J Path 1994;145:876–82.Google Scholar
  16. 16.
    Halloran PF, Madrenas J. The regulation of MHC transcription. Transplantation 1990;50:725–38.PubMedGoogle Scholar
  17. 17.
    Fleming KA, McMichael A, Morton JA, Woods J, McGee J. Distribution of HLA class I antigens in normal human tissue and in mammary cancer. J Clin Pathol 1981;34:779–84.PubMedGoogle Scholar
  18. 18.
    Daar AS, Fuggle SV, Fabre JW, Ting A, Morris PJ. The detailed distribution of HLA-A, B, C antigens in normal human organs. Transplantation 1984;38:287–92.PubMedGoogle Scholar
  19. 19.
    Natali PG, Bigotti A, Nicotra MR, Viora M, Manfredi D, Ferrone S. Distribution of human class I (HLA-A,B, C) histocompatibility antigens in normal and malignant tissues of non-lymphoid origin. Cancer Research 1984;44:4679–87.PubMedGoogle Scholar
  20. 20.
    Appleyard ST, Dunn MJ, Rose ML, Dubowitz V. Increased expression of HLA ABC class I antigens by muscle fibers in Duchenne dystrophy, inflammatory myopathy and other neuromuscular disorders. Lancet 1985;1:361–3.PubMedGoogle Scholar
  21. 21.
    Rose ML, Coles MI, Griffin RJ, Pomerance A, Yacoub MH. Expression of class I and class II major histocompatibility antigens in normal and transplanted human heart. Transplantation 1986;41: 776–80.PubMedGoogle Scholar
  22. 22.
    Suitters AJ, Rose ML, Higgins A, Yacoub MH. MHC antigen expression in sequential biopsies from transplant patients-correlation with rejection. Clin Experimental Immunology 1987;69: 575–83.Google Scholar
  23. 23.
    Ahmed-Ansari A, Tadros TS, Knopf WD, Murphy DA, Hertzler G, Feighan J, Letherby A, Sell KW. Histocompatibility complex class I and class II expression by myocytes in cardiac biopsies post-transplantation. Transplantation 1988;45:972–8.PubMedGoogle Scholar
  24. 24.
    Steinhoff G, Wonigeit K, Schafers HJ, Haverich A. Sequential analysis of monomorphic and poly-morphic major histocompatibility complex antigen expression in human heart allograft biopsy specimens. J Heart Transplant 1989;8:360–7.PubMedGoogle Scholar
  25. 25.
    Milton AD, Fabre JW Massive induction of donor type class I and class II major histocompatibility complex antigens during heart allograft rejection in the rat. J Experimental Medicine 1985; 161:98–112.Google Scholar
  26. 26.
    Ungureanu-Longrois D, Balligand JL, Simmons WW, Okada I, Kobzik L, Lowenstein CJ, Kunkel SL, Michel T, kelly RA, Smith TW Induction of nitric oxide synthase activity by cytokines in venticular myocytes is necessary but not sufficient to decrease contractile responses to beta-adrenergic agonists. Circulation Research 1995;77:494–502.PubMedGoogle Scholar
  27. 27.
    Matsumori A, Yamada T, Suzuki H, Matoba Y, Sasayama S. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. British Heart J 1994;72:561–6.Google Scholar
  28. 28.
    Labarrere CA, Mclntyre JA, Halbrook H, Faulk WP. Major histocompatibility antigens in transplanted human hearts for perfusion. J Heart Lung Transplant 1991;10:409–15.PubMedGoogle Scholar
  29. 29.
    Hart DNJ, Fabre JW. Demonstration and characterization of Ia-positive dendritic cells in the interstial connective tissues of rat hearts and other tissues but not brain. J Exper Medicine 1981; 153:347–61.Google Scholar
  30. 30.
    Carforio ALP, Botazzo GF, Counihan PJ, Burke M, Poloniecki J, Davies MJ, Pepper JR. Class II major histocompatibility complex antigens on cardiac endothelium: an early marker of rejection in the transplanted human heart. Transpl Proceedings 1990;22:1830–3.Google Scholar
  31. 31.
    Hengstenberg C, Rose ML, Page C, Taylor PM, Yacoub MH. Immunocytochemical changes suggestive of damage to endothelial cells during rejection of human cardiac allografts. Transplantation 1990;49:895–9.PubMedGoogle Scholar
  32. 32.
    Page C, Rose ML, Piggott R, Yacoub MH. Heterogeneity of vascular endothelial cells. Am J Pathol 1993;141:673–83.Google Scholar
  33. 33.
    Fuggle SV, Errasti P, Daar AS, Fabre JW, Ting A, Morris PJ. Localization of major histocompatibility complex antigens (HLA-ABC and DR) antigens in 46 kidneys. Transplantation 1983; 35:385–90.PubMedGoogle Scholar
  34. 34.
    Carlquist JF, Hammond ME, Yowell RL, O’Connell J, Anderson JL. Correlation between class II antigen (DR) expression and interleukin-2 induced lymphocyte proliferation during acute cardiac allograft rejection. Transplantation 1990;50:582–8.PubMedGoogle Scholar
  35. 35.
    Taylor PM, Rose ML, Yacoub MH, Pigott R. Induction of vascular adhesion molecules during rejection of human cardiac allografts. Transplantation 1992;54:451–7.PubMedGoogle Scholar
  36. 36.
    Labarrere CA, Pitts D, Nelson DR, Faulk WP. Coronary artery disease in cardiac allografts; association with arteriolar endothelial HLA-DR and ICAM-1 antigens. Transplant Proc 1995;27: 1939–40.PubMedGoogle Scholar
  37. 37.
    Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994;76:301–14.PubMedGoogle Scholar
  38. 38.
    Herskovitz A, Mayne AE, Willoughby SB, Kanter K, Ansari AA. Patterns of myocardial cell adhesion molecule expression in human endomyocardial biopsies after cardiac transplantation. Am J Path 1994;145:1082–94.Google Scholar
  39. 39.
    Briscoe DM, Yeung AC, Schoen EL, Allred EN, Stravrakis G, Ganz P, Cotran RS, Pober JS. Predictive value of inducible endothelial cell adhesion molecule expression for acute rejection of human cardiac allografts. Transplantation 1995;59:204–11.PubMedGoogle Scholar
  40. 40.
    Elices MJ, Osborn L, Takada Y, et al. VCAM-1 on activated endothelium interacts with leukocyte antigen VLA-4 at a site distinct from the VLA-4 fibronectin binding site. Cell 1990;60:577–82.PubMedGoogle Scholar
  41. 41.
    Stepkowski SM, Tu Y, Condon TP, Bennett CF. Blocking of heart allograft rejection by intercellular adhesion molecule-1 antisense oligonucleotides alone or in combination with other immunosuppressive modalities. J Immunol 1994:153:5336–46 [published erratum appears in J Immunol 1995;1:154:1521].PubMedGoogle Scholar
  42. 42.
    Isobe M, Suzuki J, Yamazaki S, Sekiguchi M. Acceptance of primary skin graft after treatment with anti-inter cellular adhesion molecule-land anti-leukocyte function-associated antigen-1 monoclonal antibodies in mice. Transplantation 1996;62:411–13.PubMedGoogle Scholar
  43. 43.
    Brandt M, Steinmann J, Steinhoff G, Haverich A. Treatment with monoclonal antibodies to ICAM-1 and LFA-1 in rat heart allograft rejection. Transpant Int 1997;10:141–4.Google Scholar
  44. 44.
    Schowengerdt KO, Zhu JY, Stepkowski SM, Tu Y, Entman ML, Ballantyne CM. Cardiac allograft survival in mice deficient in intercellular adhesion molecule-1. Circulation 1995;92:82–7.PubMedGoogle Scholar
  45. 45.
    Lechler RJ, Batchelor JR. Restoration of immunogenecity to passenger cells depleted kidney allografts by the addition of donor strain dendritic cells. J Exper Med 1982;155:31–41.Google Scholar
  46. 46.
    Savage COS, Hughes CWC, Mclntyre BW, Picard JK, Pober JS. Human CD4+ T cells proliferate to HLA-DR+ allogeneic vascular endothelium. Identification of accessory interactions. Transplantation 1993;56:128–34.PubMedGoogle Scholar
  47. 47.
    Page C, Thompson C, Yacoub MH, Rose ML. Human endothelial stimulation of allogeneic T cells via a CTLA-4 independent pathway. Transplant Immunology 1994;2:342–7.PubMedGoogle Scholar
  48. 48.
    Pober JS, Orosz CG, Rose ML, Savage COS. Can graft endothelial cells initiate a host anti-graft response? Transplantation 1996;63 (in Press) Google Scholar
  49. 49.
    Linsley PS, Ledbetter JA. The role of the CD28 receptor during T cell responses to antigen. Ann Rev Immunol 1993;11:192–212.Google Scholar
  50. 50.
    Noelle RJ, Roy M, Shepherd DM, Stamenkovic I, Ledbetter JA, Aruffo A. A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc Natl Acad Sci 1992;89:6550–4.PubMedGoogle Scholar
  51. 51.
    Buhlmann JE, Foy TM, Aruffo A, Crassi KM, Ledbetter JA, Green WR, Xu JC, Schultz LD, Roopesian D, Flavell RA. In the absence of CD40 signal, B cells are tolerogenic. Immunity 1995;2:645–53.PubMedGoogle Scholar
  52. 52.
    Muller DL, Jenkins MK, Schwartz RH. Clonal expansion versus functional clonal inactivation: a costimulatory signaling pathway determines the outcome of T cell antigen receptor occupancy. Ann Rev Immunol 1989;7:445–80.Google Scholar
  53. 53.
    Pearson TC, Alexander DZ, Winn KJ, Linsley PS, Lowry RP, Larsen CP. Transplantation tolerance induced by CTLA4-Ig. Transplantation 1994;57:1701–6.PubMedGoogle Scholar
  54. 54.
    Larsen CP, Alexander DZ, Hollenbaugh D, Elwood ET, Ritchie SC, Aruffo A, Hendriz R, Pearson TC. CD40-gp39 interactions play a critical role during allograft rejection. Suppression of allograft rejection by blockade of the CD40-gp39 pathway. Transplantation 1996;61:4–9.PubMedGoogle Scholar
  55. 55.
    Larsen CP, Elwood ET, Alexander DZ, Ritchie SC, Hendriz R, Tucker P, Burden C, Cho HR, Aruffo A, Hollenbaugh D, Linsley PS, Winn KJ, Pearson TC. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CDE28 pathways. Nature 1996;381:434–8.PubMedGoogle Scholar
  56. 56.
    Ruel RM, Fang JC, Denton MD, Geehan C, Long C, Mutchell RN, Ganz P, Briscoe DM. CD40 and CD40 liogand (CD 154) are coexpressed on microvessels in vivo in human cardiac allograft rejection. Transplantation 1997;64:1765–74.Google Scholar
  57. 57.
    Mach M, Schonbeck U, Sukhova GK, Bourcier T, Bonnefoy JY, Pober JS, Libby P. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells and macrophages: implication for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci 1997;94: 1931–6.PubMedGoogle Scholar
  58. 58.
    Houer LW, de los Santos RP, Hoyer JR. Antihaemophilic factor antigen: localization in endothelial cells by immunofluorescent microscopy. J Clin Investigation 1973;52:2737–44.Google Scholar
  59. 59.
    Labarrere CA, Pitts D, halbrook H, Faulk PW. Natural anticoagulant pathways in normal and transplanted human hearts. J Heart Lung Transplant 1992; 11:342–7.PubMedGoogle Scholar
  60. 60.
    Schultz R, Panas DL, Catena R, Moncada S, Olley PM, Lopachuk GD. The role of nitric oxide in cardiac depression induced by interleukin-1 beta and tumor necrosis factor alpha. Br J Pharm 1995;114:27–34.Google Scholar
  61. 61.
    Arbustini E, Grasso M, Diegoli M, Bramerio M, Scott Foglienei A, Albertario M, Matinelli L, Gavazzi A, Goggi C, Camapna C, Vigano M. Expression of tumor necrosis factor in human acute cardiac rejection. An immunohistochemical and immunoblorting study. Am J Pathol 1991; 139: 709–15.PubMedGoogle Scholar
  62. 62.
    Ruan XM, Qiao JH, Trento A, Czer LS, Blanche C, Fishbein MC. Cytokine expression and endothelial cell and lymphocyte activation in human cardiac allograft rejection: an immunocytohistochem-ical study of endomyocardial samples. J Heart Lung Transplant 1992;11:110–15.Google Scholar
  63. 63.
    Noronha IL, Eberlein Gonska M, Hartley B, Stephens S, Cameron JS, Waldherr R. in situ expression of tumor necrosis factor alpha, interferon gamma, and interleukin-2 receptors in renal allograft biopsies. Transplantation 1992;54:1017–24.PubMedGoogle Scholar
  64. 64.
    Cunningham DA, Dunn MJ, Yacoub MH, Rose ML. Local production of cytokines in the human cardiac allograft. Transplantation 1994;57:133–7.Google Scholar
  65. 65.
    Dallman MJ, Larsen CP, Morris PJ. Cytokine gene transcription in vascularized organ grafts: analysis using semiquantitative polymerase chain reaction. J Exper Med 1991;174:493–6.Google Scholar
  66. 66.
    Wu CJ, Lovett M, Wong-Lee J, Moeller F, Kitamura M, Goralski TJ, Billingham ME, Starnes VA, Clayberger C. Cytokine gene expression in rejecting cardaic allografts. Transplantation 1992;54: 326–32.PubMedGoogle Scholar
  67. 67.
    Azzawi M, Hasleton PS, Grant SCD, Stewart JP, Hutchinson IV. Interleukin-10 in human heart transplantation: an in situ hybridization study. J Heart Lung Transplant 1995;14:519–28.PubMedGoogle Scholar
  68. 68.
    Nickerson P, Steurer W, Stiger J, Zheng X, Steele AW, Strom TB. Cytokines and the Thl/Th2 paradigm in transplantation. Curr Opin Immunol 1994;6:757–64.PubMedGoogle Scholar
  69. 69.
    Seder RA, Gazzinelli R, Sher A, Paul WE. Interleukin 12 acts directly on CDE4+T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming. Proc Natl Acad Sci 1993;90:10188–92.PubMedGoogle Scholar
  70. 70.
    Giri JG, Ahdieh M, Eisenman J, Shanebeck K, Brabstein K, Kumaki S, Namen A, Park LS, Cosman D, Anderson D. Utilization of the beta and gamma chains of theIL-2 receptor by the novel cytokine IL-15. EMBO J 1994;13:2822–30.PubMedGoogle Scholar
  71. 71.
    Russell ME. Macrophage and transplant ateriosclerosis: known and novel molecules. J Heart Lung Transplant 1995;14:S111–15.PubMedGoogle Scholar
  72. 72.
    Pavlakis M, Strehlau J, Lipman M, Shapiro M, Maslinski W, Strom TB. Intragraft IL-15 transcripts are increased in human renal allograft rejection. Transplantation 1996;62:543–5.PubMedGoogle Scholar
  73. 73.
    van Gilder T, Baan CC, Balk AH, Koop CJ, Howler CT, van deer Meer P, Mocha B, Zondervan PE, Niesters HG, Weimar W. Blockade of interleukin (IL)-2/IL-2 receptor pathway with a monoclonal anti-IL-2 receptor antibody (BT 563) does not prevent the development of acute heart allograft rejection in humans. Transplantion 1998;65:405–10.Google Scholar
  74. 74.
    Yang X, Chowdhury N, Cai B, et al. Induction of myocardial nitric oxide synthase by cardiac allograft rejection. J Clin Invest 1994;94:714–21.PubMedGoogle Scholar
  75. 75.
    Worrall NK, Chang K, Suau GM, et al. Inhibition of inducible nitric oxide synthase prevents myocardial and systemic vascular barrier dysfunction during early cardiac allograft rejection. Circ Research 1996;78:769–79.Google Scholar
  76. 76.
    Worrall NK, Misko TP, Sullivan PM, Hui JJ, Rodi CP, Ferguson TB. Corticosteroids inhibit expression of inducible nitric oxide synthase during acute cardiac allograft rejection. Transplantation 1996;61:324–8.PubMedGoogle Scholar
  77. 77.
    Cai B, Roy DK, Sciacca R, Michler RE, Cannon PJ. Effects of immunosuppressive therapy on expression of inducible nitric oxide synthase (iNOS) during cardiac allograft rejection. Int J Cardiol 1995;50:243–51.PubMedGoogle Scholar
  78. 78.
    Cui S, Reichner JS, Mateo RB, Albina JE. Activated murine macrophages induce apoptosis in tumor cells through nitric oxide-dependent or—independent mechanisms. Cancer Res 1994;54:2462–7.PubMedGoogle Scholar
  79. 79.
    Szabolcs M, Michler RE, Yang X, et al. Apoptosis of cardiac myocytes during cardiac allograft rejection. Relation to induction of nitric oxide synthase. Circulation 1996;94:1665–73.PubMedGoogle Scholar
  80. 80.
    Szabolcs MJ, Ravalli S, Minanov O, Sciacca RR, Michler RE, Canjnon PJ. Apoptosis and increased expression of inducible nitric oxide synthase in human allograft rejection. Transplantation 1998;65:804–12.PubMedGoogle Scholar
  81. 81.
    Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Eng J Med 1969;280:735–9.Google Scholar
  82. 82.
    Auchincloss H. Xenografting: a review. Transplantation Reviews 1990;4:14–27.Google Scholar
  83. 83.
    Brasile L, Zerbe T, Rabin B, et al. Identification of the antibody to vascular endothelial cells in patients undergoing cardiac transplantation. Transplantation 1985;40:672–5.PubMedGoogle Scholar
  84. 84.
    Trento A, Hardesty RL, Griffith BP, et al. Role of the antibody to vascular endothelial cells in hyperacute rejection in patients undergoing cardiac transplantation. J Thor and Cardiovasc Surg 1988;95:37–41.Google Scholar
  85. 85.
    Kemnitz J, Cremer J, Restropo-Specht I, et al. Hyperacute rejection in heart allografts. Path Res and Practice 1991;187:23–9.Google Scholar
  86. 86.
    Weill R, Clarke DR, Iwaki Y, et al. Hyperacute rejection of a transplanted human heart. Transplantation 1981;32:71–2.Google Scholar
  87. 87.
    Singh G, Thompson M, Griffith B, et al. Histocompatibility in cardiac transplantation with particular reference to immunopathology of positive serologic crossmatch. Clin Immunology and Immunopatholgy 1983;28:56–66.Google Scholar
  88. 88.
    Yacoub M, Ferstenstein H, Doyle P, et al. The influence of HLA matching in cardiac allograft recipients receiving cyclosporine and azathioprine. Transplant Proc 1987;19:2487–9.PubMedGoogle Scholar
  89. 89.
    McCloskey D, Ferstenstein H, Banner N, et al. The effect of HLA lymphocytotoxic antibody status and crossmatch on cardiac transplant survival. Transplan Proc 1989;21:804–6.Google Scholar
  90. 90.
    Smith JD, Danskine AJ, Laylor RM, et al. The effect of panel reactive antibodies and the donor specific crossmatch on graft survival after heart and lung transplantation. Transplant Immunology 1993;1:60–5.PubMedGoogle Scholar
  91. 91.
    Lavee J, Kormos RL, Duquesnoy RJ, et al. Influence of panel-reactive antibody and lymphocytotoxic crossmatch on survival after heart transplantation. J Heart Lung Transpl 1991;10:921–30.Google Scholar
  92. 92.
    Taylor CJ, Chapman JR, Ting A, et al. Characterization of lymphocytotoxic antibodies causing a positive crossmatch in renal transplantation. Transplantation 1989;48:953–8.PubMedGoogle Scholar
  93. 93.
    Cerilli J, Brasile L, Galouzis T, et al. The vascular endothelial cell antigen system. Transplantation 1985;39:286–9.PubMedGoogle Scholar
  94. 94.
    Billingham ME, Cary NRB, Hammond EH, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: heart rejection study group. J Heart Transp 1990;9:587–91.Google Scholar
  95. 95.
    Schuurman HJ, Jambroes G, Borleffs JCC, et al. Acute humoral rejection after heart transplantation. Transplantation 1988;46:603–5.PubMedGoogle Scholar
  96. 96.
    Schuurman HJ, Gmelig-Meyling FHJ, Wijngaard PLJ, et al. Endomyocardial biopsies after heart transplantation. Transplantation 1989;48:435–8.PubMedGoogle Scholar
  97. 97.
    Wijngaard PL, van der Meulen A, Schuurman HJ, et al. Cytoimmunologic monitoring for the diagnosis of acute rejection after heart transplantation. Transpl Proceedings 1989;21:2521–2.Google Scholar
  98. 98.
    Hammond EH, Yowell RL, Nunoda S, et al. Vascular (humoral) rejection in heart transplantation: pathologic observations and clinical implications. J Heart Transplant 1989;8:430–43.PubMedGoogle Scholar
  99. 99.
    Maisch B, Hufhagel G, Bauer E, et al. Value of immunohistological and immunoserological monitoring in cardiac transplantation. Eur Hear J 1987;8:29–34.Google Scholar
  100. 100.
    Harkiss GD, Cave P, Brown DL, et al. Anti-heart antibodies in cardiac allograft recipients. Int Arch Allergy and Applied Immunology 1984;73:18–22.Google Scholar
  101. 101.
    Lowry PJ, Thompson RA, Littler WA. Humoral immunity in cardiomyopathy. Br Heart J 1983; 50:390–4.PubMedGoogle Scholar
  102. 102.
    Cherry R, Nielson H, Reed E, Reemsta K, Suciu-Foca N, Marboe C. Vascular (humoral) rejection in human cardiac allograft biopsies: relation to circulating anti-HLA antibodies. J Heart Lung Transplantation 1992;11:24–30.Google Scholar
  103. 103.
    Labarrere CA, Pitts D, Halbrook H, Page Faulk W. Immunoglobulin M antibodies in transplanted human hearts. J Heart Lung Transplantation 1993;12:394–402.Google Scholar
  104. 104.
    Page Faulk W, Labarrere CA, Pitts D, Halbrook H. Vascular lesions in biopsy specimens devoid of cellular infiltrates: qualitative and quantitative immunocytochemical studies of human cardiac allografts. J Heart Lung Transplantation 1993;12:219–29.Google Scholar
  105. 105.
    Simmonds J, Price R, Corbett J, et al. Enhanced chemiluminescence detection of Western blotted proteins from two-dimensional SDS PAGE. In: Dunn MJ (ed):2-D PAGE ‘91: Proceedings of the International Meeting on Two-Dimensional Electrophoresis. London, NHLI, 1991, pp. 46–8.Google Scholar
  106. 106.
    Dunn MJ, Rose ML, Latif N, et al. Demonstration by Western blotting of antiheart antibodies before and after cardiac transplantation. Transplantation 1991;51:806–12.PubMedGoogle Scholar
  107. 107.
    Fenoglio J, Ho E, Reed E, et al. Anti-HLA antibodies and heart allograft survival. Transpl Proceedings 1989;21:807–9.Google Scholar
  108. 108.
    Smith JD, Danskine AJ, Rose ML, et al. Specificity of lymphocytotoxic antibodies formed after cardiac transplantation and correlation with rejection episodes. Transplantation 1992;53:1358–62.PubMedGoogle Scholar
  109. 109.
    Suciu-Foca N, Reed N, Marboe C, et al. The role of anti-HLA antibodies in heart transplantation. Transplantation 1991;51:716–24.PubMedGoogle Scholar
  110. 110.
    Opeltz G, Graver B, Mickey R, et al. Lymphocytotoxic antibody responses to transfusions in potential kidney transplant recipients. Transplantation 1981;32:177–83.Google Scholar
  111. 111.
    Scornick JC, Ireland JE, Howard J, et al. Assessment of the risk for broad sensitization by blood transfusions. Transplantation 1984;37:249–52.Google Scholar
  112. 112.
    Ross R. The pathogenesis of atherosclerosis-an update. N Eng J Med 1986;314:488–500.Google Scholar
  113. 113.
    Hornick P, Smith JS, Pomerance A, Mitchell A, Banner NJ, Rose ML, Yaoub MH. Influence of acute rejection episodes, HLA matching and donor/recipient phenotype on the development of early transplant-associated coronary artery disease. Circulation 1997;96: II-48–II-53.Google Scholar
  114. 114.
    Hornick P, Mason PD, Yacoub MH, Rose ML, Batchelor R, Lechler RL. Assessment of the contribution that direct allorecognition makes to the progression of chronic cardiac transplant rejection in humans. Circulation 1998;97:1257–63.PubMedGoogle Scholar
  115. 115.
    Dunn MJ, Crisp S, Rose ML, et al. Detection of anti-endothelial antibodies by Western blotting-positive correlation with coronary artery disease after cardiac transplantation. Lancet 1992;39: 1566–70.Google Scholar
  116. 116.
    Crisp SJ, Dunn MJ, Rose ML, Barbir M, Yacoub MH. Anti-endothelial antibodies after heart transplantation: the accelerating factor in transplant-associated coronary artery disease. J Heart Lung Transplant 1994;13:81–92.PubMedGoogle Scholar
  117. 117.
    Wheeler CH, Collins A, Dunn MJ, Crisp SJ, Yacoub MH, Rose ML. Characterization of endothelial antigens associated with transplant associated coronary artery disease. J Heart Lung Transplantation 1995;14:S188–97.Google Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Marlene L. Rose
    • 1
  • Sudhir Kushwaha
    • 1
  • Deirdre Cunningham
    • 1
  1. 1.National Heart and Lung Institute, Imperial College School of MedicineHarefield and Brompton HospitalHarefield, MiddlesexUK

Personalised recommendations